Beijing SL Pharmaceutical Co Ltd (002038) - Net Assets

Latest as of September 2025: CN¥5.70 Billion CNY ≈ $834.20 Million USD

Based on the latest financial reports, Beijing SL Pharmaceutical Co Ltd (002038) has net assets worth CN¥5.70 Billion CNY (≈ $834.20 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥6.03 Billion ≈ $882.19 Million USD) and total liabilities (CN¥327.96 Million ≈ $47.99 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check financial resilience of Beijing SL Pharmaceutical Co Ltd to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric	Value
Current Net Assets	CN¥5.70 Billion
% of Total Assets	94.56%
Annual Growth Rate	21.26%
5-Year Change	11.95%
10-Year Change	54.45%
Growth Volatility	42.07

Beijing SL Pharmaceutical Co Ltd - Net Assets Trend (2001–2024)

This chart illustrates how Beijing SL Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. Also explore 002038 total assets for the complete picture of this company's asset base.

Annual Net Assets for Beijing SL Pharmaceutical Co Ltd (2001–2024)

The table below shows the annual net assets of Beijing SL Pharmaceutical Co Ltd from 2001 to 2024. For live valuation and market cap data, see Beijing SL Pharmaceutical Co Ltd market cap and net worth.

Year	Net Assets	Change
2024-12-31	CN¥5.58 Billion ≈ $816.62 Million	-3.95%
2023-12-31	CN¥5.81 Billion ≈ $850.19 Million	+6.04%
2022-12-31	CN¥5.48 Billion ≈ $801.78 Million	+2.87%
2021-12-31	CN¥5.33 Billion ≈ $779.39 Million	+6.85%
2020-12-31	CN¥4.98 Billion ≈ $729.42 Million	+3.39%
2019-12-31	CN¥4.82 Billion ≈ $705.49 Million	+6.70%
2018-12-31	CN¥4.52 Billion ≈ $661.20 Million	+5.10%
2017-12-31	CN¥4.30 Billion ≈ $629.14 Million	+9.40%
2016-12-31	CN¥3.93 Billion ≈ $575.09 Million	+8.77%
2015-12-31	CN¥3.61 Billion ≈ $528.73 Million	+13.58%
2014-12-31	CN¥3.18 Billion ≈ $465.50 Million	+22.87%
2013-12-31	CN¥2.59 Billion ≈ $378.85 Million	+22.61%
2012-12-31	CN¥2.11 Billion ≈ $308.98 Million	+25.27%
2011-12-31	CN¥1.69 Billion ≈ $246.66 Million	+39.15%
2010-12-31	CN¥1.21 Billion ≈ $177.26 Million	+23.22%
2009-12-31	CN¥983.06 Million ≈ $143.85 Million	+28.91%
2008-12-31	CN¥762.61 Million ≈ $111.59 Million	+38.17%
2007-12-31	CN¥551.93 Million ≈ $80.76 Million	+29.50%
2006-12-31	CN¥426.20 Million ≈ $62.37 Million	+11.43%
2005-12-31	CN¥382.49 Million ≈ $55.97 Million	+5.82%
2004-12-31	CN¥361.45 Million ≈ $52.89 Million	+214.17%
2003-12-31	CN¥115.05 Million ≈ $16.84 Million	+34.39%
2002-12-31	CN¥85.61 Million ≈ $12.53 Million	+29.14%
2001-12-31	CN¥66.29 Million ≈ $9.70 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Beijing SL Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have grown by 17965.6% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2024)

Component	Amount	Percentage
Retained Earnings	CN¥3.85 Billion	69.08%
Common Stock	CN¥1.03 Billion	18.44%
Other Comprehensive Income	CN¥695.07 Million	12.47%
Other Components	CN¥430.42K	0.01%
Total Equity	CN¥5.57 Billion	100.00%

Beijing SL Pharmaceutical Co Ltd Competitors by Market Cap

The table below lists competitors of Beijing SL Pharmaceutical Co Ltd ranked by their market capitalization.

Company	Market Cap
Brookline Bancorp Inc NASDAQ:BRKL	$975.70 Million
Qisda Corp TW:2352	$975.88 Million
Triveni Engineering & Industries Limited NSE:TRIVENI	$975.92 Million
Biotest Aktiengesellschaft XETRA:BIO	$976.15 Million
Longyan Zhuoyue New Energy Co Ltd SHG:688196	$975.64 Million
Fujian Apex Software Co Ltd SHG:603383	$975.53 Million
Everlight Chemical Industrial Corp TW:1711	$975.03 Million
Heilongjiang ZBD Pharmaceutical Co Ltd SHG:603567	$974.90 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Beijing SL Pharmaceutical Co Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

From 2023 to 2024, total equity changed from 5,800,616,100 to 5,572,447,942, a change of -228,168,158 (-3.9%).
Net loss of 74,065,656 reduced equity.
Dividend payments of 154,102,500 reduced retained earnings.

Equity Change Factors (2023 to 2024)

Factor	Impact	Contribution
Net Income	CN¥-74.07 Million	-1.33%
Dividends Paid	CN¥154.10 Million	-2.77%
Other Changes	CN¥-2.00	-0.0%
Total Change	CN¥-	-3.93%

Book Value vs Market Value Analysis

This analysis compares Beijing SL Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 1.23x
The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
The price-to-book ratio has decreased from 100.58x to 1.23x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2001-12-31	CN¥0.06	CN¥6.49	x
2002-12-31	CN¥0.08	CN¥6.49	x
2003-12-31	CN¥0.11	CN¥6.49	x
2004-12-31	CN¥0.53	CN¥6.49	x
2005-12-31	CN¥0.38	CN¥6.49	x
2006-12-31	CN¥0.63	CN¥6.49	x
2007-12-31	CN¥0.54	CN¥6.49	x
2008-12-31	CN¥0.74	CN¥6.49	x
2009-12-31	CN¥0.95	CN¥6.49	x
2010-12-31	CN¥1.16	CN¥6.49	x
2011-12-31	CN¥1.59	CN¥6.49	x
2012-12-31	CN¥1.98	CN¥6.49	x
2013-12-31	CN¥2.49	CN¥6.49	x
2014-12-31	CN¥3.06	CN¥6.49	x
2015-12-31	CN¥3.48	CN¥6.49	x
2016-12-31	CN¥3.79	CN¥6.49	x
2017-12-31	CN¥4.16	CN¥6.49	x
2018-12-31	CN¥6.57	CN¥6.49	x
2019-12-31	CN¥4.64	CN¥6.49	x
2020-12-31	CN¥4.84	CN¥6.49	x
2021-12-31	CN¥5.17	CN¥6.49	x
2022-12-31	CN¥5.32	CN¥6.49	x
2023-12-31	CN¥5.71	CN¥6.49	x
2024-12-31	CN¥5.27	CN¥6.49	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Beijing SL Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): -1.33%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: -11.21%
• Asset Turnover: 0.11x
• Equity Multiplier: 1.07x
Recent ROE (-1.33%) is below the historical average (16.56%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2001	28.52%	58.74%	0.42x	1.16x	CN¥12.28 Million
2002	22.54%	38.66%	0.49x	1.20x	CN¥10.73 Million
2003	27.14%	43.91%	0.47x	1.32x	CN¥19.70 Million
2004	8.86%	34.39%	0.24x	1.08x	CN¥-4.13 Million
2005	8.86%	28.53%	0.29x	1.06x	CN¥-4.37 Million
2006	11.24%	33.24%	0.31x	1.08x	CN¥5.30 Million
2007	24.45%	56.75%	0.40x	1.06x	CN¥79.67 Million
2008	28.65%	60.85%	0.45x	1.04x	CN¥141.82 Million
2009	25.28%	62.59%	0.38x	1.06x	CN¥147.55 Million
2010	22.90%	59.57%	0.37x	1.05x	CN¥153.64 Million
2011	32.23%	84.03%	0.36x	1.07x	CN¥360.95 Million
2012	23.58%	47.77%	0.45x	1.09x	CN¥277.00 Million
2013	22.50%	49.70%	0.43x	1.06x	CN¥320.83 Million
2014	22.08%	55.92%	0.37x	1.05x	CN¥380.29 Million
2015	16.07%	49.72%	0.31x	1.05x	CN¥217.26 Million
2016	11.60%	44.77%	0.25x	1.05x	CN¥62.46 Million
2017	12.49%	42.96%	0.27x	1.07x	CN¥106.51 Million
2018	12.70%	26.36%	0.43x	1.11x	CN¥121.66 Million
2019	10.12%	23.98%	0.39x	1.09x	CN¥5.96 Million
2020	7.33%	32.78%	0.21x	1.08x	CN¥-132.75 Million
2021	8.02%	35.06%	0.21x	1.08x	CN¥-105.21 Million
2022	4.29%	22.32%	0.18x	1.07x	CN¥-312.40 Million
2023	7.18%	40.92%	0.16x	1.08x	CN¥-163.37 Million
2024	-1.33%	-11.21%	0.11x	1.07x	CN¥-631.31 Million

Industry Comparison

This section compares Beijing SL Pharmaceutical Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

Industry: Drug Manufacturers - Specialty & Generic
Average net assets among peers: $3,784,080,233
Average return on equity (ROE) among peers: 10.27%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Beijing SL Pharmaceutical Co Ltd (002038)	CN¥5.70 Billion	28.52%	0.06x	$975.67 Million
Shenzhen Neptunus Bioengineering Co Ltd (000078)	$52.15 Million	21.80%	0.58x	$1.22 Billion
Anhui Fengyuan Pharmaceutical Co Ltd (000153)	$24.03 Million	18.61%	1.45x	$438.59 Million
Shan Dong Dong-E E-Jiao Co Ltd (000423)	$1.05 Billion	10.46%	0.19x	$5.18 Billion
Livzon Pharmaceutical Group Inc (000513)	$3.01 Billion	11.93%	0.53x	$2.81 Billion
Wedge Industrial Co Ltd (000534)	$654.70 Million	1.92%	0.87x	$2.95 Billion
Yunnan Baiyao Group Co Ltd (000538)	$19.92 Billion	17.54%	0.52x	$13.85 Billion
Hainan Haiyao Co Ltd (000566)	$1.33 Billion	7.89%	0.52x	$949.23 Million
Tus Pharmaceutical Group Co Ltd (000590)	$268.54 Million	1.60%	1.47x	$391.07 Million
Northeast Pharmaceutical Group Co Ltd (000597)	$870.26 Million	1.00%	1.90x	$1.03 Billion
Jilin Aodong Pharmaceutical Group Co Ltd (000623)	$10.66 Billion	9.94%	0.14x	$3.30 Billion

About Beijing SL Pharmaceutical Co Ltd

SHE:002038 China Drug Manufacturers - Specialty & Generic

Market Cap

$975.67 Million

CN¥6.67 Billion CNY

Market Cap Rank

#9215 Global

#2482 in China

Share Price

CN¥6.49

Change (1 day)

-3.85%

52-Week Range

CN¥5.50 - CN¥8.98

All Time High

CN¥10151.79